
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HRASLS3 CRISPR/Cas9 KO Plasmid (h) | sc-409231 | 20 µg | $397.00 | |||
HRASLS3 HDR Plasmid (h) | sc-409231-HDR | 20 µg | $445.00 |
PLA2G16 encodes HRASLS3, a phospholipase/acyltransferase implicated in remodeling membrane phospholipids and regulating lipid-derived signaling mediators. HRASLS3 activity can influence membrane dynamics, fatty acid metabolism, and cellular stress responses that intersect with pathways controlling proliferation and survival. By modulating lipid signaling microenvironments, PLA2G16 has been studied in contexts including oncogenic signaling networks and metabolic reprogramming, where altered lipid homeostasis contributes to disease-associated phenotypes. These functions make HRASLS3 a useful target for dissecting links between membrane lipid composition, signaling output, and cell-state transitions.
HRASLS3 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PLA2G16 gene in human cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the PLA2G16 locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.
When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.
For applications requiring confirmed, selectable knockout clones, HRASLS3 HDR Plasmid (h) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined PLA2G16 target site.
When co-transfected with HRASLS3 CRISPR/Cas9 KO Plasmid (h):
The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the PLA2G16 locus and eliminating potential confounding effects on downstream assays.
This two-step approach:
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.